Sofnobrutinib - Carna Biosciences
Alternative Names: AS-0871; AS-871Latest Information Update: 28 Feb 2025
At a glance
- Originator Carna Biosciences
- Developer Carna Biosciences; Evotec SE
- Class Anti-inflammatories; Small molecules; Triazines
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis; Autoimmune disorders; Inflammation
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Atopic-dermatitis in Unknown
- 28 Oct 2024 No recent reports of development identified for preclinical development in Inflammation in Japan (PO)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Netherlands (PO)